Finance cost increase from rapid expansion
Finance costs rose due to working capital needs and new machinery loans; may pressure near-term profitability.
medium · analyst_questionFredun Pharmaceuticals Ltd — Q3 FY26
Fredun Pharmaceuticals delivered a strong Q3 FY26 with revenue of ₹160.92 crore (+57% YoY), EBITDA of ₹26.34 crore (+99% YoY), and PAT of ₹10.48 crore (+96% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Seasonality and margin volatility in Q4
Q4 typically has higher revenue but lower margins due to year-end discounts and schemes.
low · management_commentaryExecution risk in new-age business scale-up
New-age brands require state-wise launches and penetration; operational leverage may take longer than expected.
medium · management_commentary